

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

[Translation]

June 22, 2022

To: Shareholders

Company name Renascience Inc.
Name of Representative: Koji Naito, President & CEO
(Security Code: 4889 TSE Growth)
Inquiries: Kazuhiro Ikeda, Director, CFO

(Change in Disclosure Item) Partial Change to "Notice Concerning Transition to a Company with an Audit & Supervisory Committee and Changes in Directors and Corporate Auditors"

The Company hereby announces that it has decided to submit a proposal to the Board of Directors Meeting on June 29, 2022 to partially change the new position of Sho Kato, Director, who is scheduled to retire, for the purpose of accelerating the speed of decision-making not only in the field of medical solutions using AI, etc., but also in R&D in general including pharmaceuticals.

Particulars

(Before the change)

2. Personnel Changes of Directors after Transition to a Company with Audit & Supervisory Committee
(3) Retiring directors and corporate auditors (to be proposed at the 23rd Ordinary General Meeting of Shareholders to be held on June 29, 2022)

Name	Former Job Title	Title after Retirement)
Sho Kato	Director, in charge of R&D	Executive officer (<u>In charge of Medical Solutions</u>)

(After the change)

2. Personnel Changes of Directors after Transition to a Company with Audit Committee System
(3) Retiring Directors and Corporate Auditors (to be proposed at the 23rd Ordinary General Meeting of Shareholders to be held on June 29, 2022)

Name	Former Job Title	(Title after retirement)
Sho Kato	Director, in charge of R&D	Executive officer (<u>In charge of Research & Development</u>)

(Note) The changes are underlined.

End